期刊
INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS
卷 39, 期 1, 页码 1-6出版社
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/ijstd.IJSTD_99_17
关键词
Diabetes mellitus; erectile dysfunction; sildenafilDiabetes mellitus; erectile dysfunction; sildenafil
Erectile dysfunction (ED) is a common complication in patients with diabetes mellitus (DM). Sildenafil, a phosphodiesterase-5 inhibitor, is commonly used in patients with ED. This meta-analysis was planned to determine the strength of evidence to assess the efficacy and tolerability of sildenafil in patients with DM-associated ED. Electronic searches were carried out to identify randomized controlled trials (RCTs) which reported clinical efficacy of sildenafil in patients with DM-associated ED. Data were extracted and methodological quality was assessed. Relative Risk (RR) with 95% confidence intervals (CIs) was estimated for the dichotomous outcomes, and the mean difference with 95% CI was estimated for continuous data. Eight randomized controlled trials (RCTs) involving 1172 patients met with our inclusion criteria. In comparison to placebo, sildenafil significantly improved the overall sexual performance in patients of ED associated with DM with relative risk (RR) of answering yes to global efficiency question being 3.99 (95% CI: 2.58u6.18) compared to placebo. The rate of discontinuation due to treatment-related adverse reactions was 2.4% in sildenafil arm with RR of 2.67 (95% CI: 0.74u9.62). Sildenafil is an effective and safe medication for the treatment of ED associated with DM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据